Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of misleading statements and failure to disclose significant operational challenges that have negatively impacted the company's financial performance [2][4]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $75,000 in RxSight between November 7, 2024, and July 8, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against RxSight, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [2][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against RxSight - The complaint alleges that RxSight and its executives violated federal securities laws by making false and misleading statements regarding the company's sales and product demand [4]. - Specific issues cited include "adoption challenges" leading to declines in sales and utilization, overstated demand for products, and an inability to meet previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second quarter 2025 financial results, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, due to significant declines in sales and lowered revenue guidance [5].

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to ...

NEW YORK, July 27, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against RxSight, Inc. ("RxSight" or the "Company")(NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether RxSight and certain of its officers and/or ...

SAN DIEGO, July 26, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the RxSight class action lawsuit – captioned Makaveev v. RxSight, Inc., No. 25-cv-01596 (C.D. Cal.) – seeks to represent purchasers or acquirers of RxSight, Inc. (NASDAQ: RXST) securities and charges RxSight as well as certain of RxSight’s executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the RxSight class action lawsuit, plea ...

Group 1 - A lawsuit has been filed against RxSight, Inc. and certain senior executives for potential violations of federal securities laws [1][2] - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities [2] - The case is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596 [2] Group 2 - RxSight manufactures and sells light adjustable intraocular lenses used in cataract surgery, with its main product being the Light Adjustable Lens (LAL) [3] - The company has faced "adoption challenges" and a slowdown in LAL utilization, which was first noted in 2024 [4] Group 3 - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price decline of approximately 38%, from $26.12 to $16.21 per share [5] - On July 8, 2025, the company further reduced its revenue forecast, resulting in another 38% decline in stock price, from $12.79 to $7.95 per share [6]

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired RxSight, Inc. (NASDAQ: RXST) securities between November 7, 2024 and July 8, 2025. RxSight is a commercial-stage medical technology company, engaged in the research and development, manufacture, and sale of light adjustable intraocular lenses (“LAL”) used in cataract surgery in the United States. The Company’s primary product is the RxSight s ...

NEWTOWN, Pa., July 25, 2025 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a leading class action law firm, is investigating securities fraud claims on behalf of all investors of RxSight, Inc. (“RxSight”) (NASDAQ: RXST) who purchased stock pursuant to the company’s statements about its business, operations, and prospects between November 7, 2024, and July 8, 2025 (the “Class Period”). To join this case, go HERE. Investors who purchased RxSight stock may move the U.S. District Court for the Central District of Ca ...

LOS ANGELES, July 25, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or "the Company") (NASDAQ: RXST) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. RxSight reported its financial results for the second quarter of 2025 on July 9, 2025. The Company reported declines in key ...

PHILADELPHIA, July 24, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC, a nationally recognized securities litigation law firm, is investigating potential securities law violations involving RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST). A class action lawsuit was recently filed on behalf of investors who acquired RxSight securities between November 7, 2024 and July 8, 2025 (the “Class Period”). Investor Deadline: Investors who purchased or acquired RxSight securities during the Class Period may, no ...

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to ...